The Point Of Care (PoC) Diagnostics Market is expanding as healthcare delivery models place greater emphasis on timely test results and flexible testing locations. Polaris Market Research reports a global market value of USD 60.99 billion in 2025, the base year, rising to USD 66.50 billion in 2026 and projected to reach USD 136.90 billion by 2034. The market is expected to register a CAGR of 9.40% during the 2026–2034 forecast period. North America accounted for 42.60% of global market share in 2025, and infectious diseases represented 33.33% of product revenue share. The report also projects that the OTC segment will grow at a CAGR of 9.9%. Key players include Abbott, BD, bioMérieux, Danaher Corporation, EKF Diagnostics Holdings plc, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, QuidelOrtho Corporation, Siemens Healthcare Private Limited, and Thermo Fisher Scientific Inc.

Testing Beyond the Central Laboratory

Point-of-care diagnostics deliver test results at or near the location where a patient receives care. Depending on the product and intended use, these solutions may be used in hospitals, clinics, laboratories, homes, and assisted-living healthcare facilities. Their value proposition is tied to making diagnostic information available in settings where it can inform the next step in a care pathway.

The report’s product categories range from glucose and HbA1c testing to coagulation, fertility, infectious diseases, cardiac markers, hematology, thyroid-stimulating hormone, lipid testing, blood gas and electrolytes, drug-abuse testing, and urinalysis. This range means buyers must assess the clinical application and operational environment of each product rather than treating PoC diagnostics as one uniform technology segment.

Consumer Access and Prescription Categories

Polaris Market Research divides the market by mode of prescription into OTC and prescription-based products. The OTC segment is expected to be the fastest-growing category, with a projected CAGR of 9.9% during the forecast period. Self-testing kits may provide consumers with access to selected tests, subject to the product’s intended use, directions, and applicable clinical guidance. Clear instructions and appropriate interpretation are important considerations when testing takes place outside a conventional healthcare facility.

By contrast, prescription-based diagnostics are used within a clinician-directed context. For providers and procurement teams, evaluating these categories involves understanding who will administer the test, how results are reviewed, and what follow-up process is available. Product usability, training, quality control, and information management can affect how well a diagnostic tool fits into an existing workflow.

Read More @ https://www.polarismarketresearch.com/industry-analysis/point-of-care-poc-diagnostics-market

Clinical Applications and End-Use Settings

Infectious diseases accounted for 33.33% of market revenue share in 2025. The report lists multiple infectious-disease applications, including HIV, hepatitis, influenza, respiratory syncytial virus, tuberculosis, and other infections. It also covers cardiac marker testing, which is a distinct product category, along with glucose, fertility, coagulation, and thyroid-related testing.

The product scope further includes urinalysis systems and primary care systems, as well as decentralized clinical chemistry. The report’s end-use categories—clinics, hospitals, home, assisted-living healthcare facilities, and laboratories—reflect the range of locations in which PoC solutions may be deployed.

For buyers assessing point-of-care testing devices, operational requirements may include sample handling, staff competency, result documentation, connectivity, maintenance, and quality assurance. These considerations help determine whether a device can be implemented consistently across a single site or a larger healthcare network.

Regional and Competitive Landscape

North America accounted for 42.60% of the global market in 2025. The report also covers Europe, Asia Pacific, Latin America, and the Middle East & Africa, providing a regional framework for assessing demand and commercialization. Market conditions and purchasing pathways can differ across regions, so companies should assess local requirements rather than assume a single launch model will apply everywhere.

The report identifies Abbott, BD, bioMérieux, Danaher Corporation, EKF Diagnostics Holdings plc, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated, QuidelOrtho Corporation, Siemens Healthcare Private Limited, and Thermo Fisher Scientific Inc. as key market participants. For suppliers and healthcare organizations, the market outlook underscores the need to align product capabilities with clinical requirements, intended users, and care settings. The report’s forecast provides a basis for tracking the sector through 2034 while keeping decisions anchored in specific applications and verified product performance.

More Trending Latest Reports By Polaris Market Research:

singapore-malaysia-and-china-corporate-secretarial-services-market

specialty-chemicals-market

listing-the-top-10-lingerie-market-companies-globally-in-2025

semaglutide-market

titanium-dioxide-tio2-market

pet-ct-scanner-device-market

green-premium-products-market

millimeter-wave-technology-market

distributed-fiber-optic-sensor-market